Search results
Showing 2001 to 2050 of 2052 results for work
Heart failure patients to be remotely monitored by technology shown to cut hospitalisations by 50%
Two technologies, HeartLogic and TriageHF, have been recommended in final diagnostic guidance.
Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in urgent care settings.
For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.
People who have had a stroke should be offered additional rehabilitation
People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover
NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.
NICE recommends a weekly injection for treating growth failure in children
This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.
NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.
We've updated our health inequalities web resource so that it maps NICE guidance to frameworks for children and young people.
An early introduction to NICE’s ongoing activity in virtual wards
How 'surrogate outcomes' influence long-term health outcomes
NICE working with international organisations to develop guidance.
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
NICE recommends life changing technology is rolled out to people with type 1 diabetes
Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.
NICE launches refreshed support service for life sciences industry
NICE has launched its refreshed support service for the life sciences sector, NICE Advice.
Thousands of appointments released for the NHS without compromising safety
Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term
To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
NICE collaboration on streamlined licensing and patient access process for new medicines
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.
Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Celebrating the people who support NICE: International Volunteer Day
Applauding the members of the public who donate their valuable experience and insight to NICE.
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
Towards a new partnership – NICE and the voluntary and community sector
Victoria Thomas gives details of NICE’s new voluntary and community sector forum.
People with a rare blood disorder have access to a new treatment following draft guidance from NICE.
People at risk of severe COVID-19 to have access to antiviral Paxlovid
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA.
Thousands of people asked each year could be missing out on brief interventions to help curb problem drinking, or a potential referral to specialist alcohol services.
170,000 people in England to have further treatment choice for preventing migraine attacks
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
NICE collaborates with international partner agencies to streamline the confidential marking process
NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.
145,000 people in England to have further treatment choice for preventing migraine attacks
NICE has for the first time recommended an oral treatment for preventing migraines.
NICE recommends genetic test to prevent newborn babies going deaf
A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.
NICE to become single point of access for Covid-19 guidance and advice
NICE announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.
New functionality for online collaboration on consultations, enables groups or organisations to submit a joined-up response.
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.
NICE and NIHR: working together to produce research with impact
Alice and Zoe discuss how the National Institute of Health Research (NIHR) and NICE work in partnership and identify key research priorities from NICE guidance.
Dr Roberts, who is a qualified doctor, has 20 years’ experience in clinical and management posts in healthcare both in the private and public sector.
Patient safety and surgical innovation – why new isn't always better
Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.
Children and young people set to benefit from new treatment for peanut allergy
Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.
Putting user needs at the heart of an advisory service for AI and data-driven technologies
Toni Gasse explains how user-needs are being placed front and centre to develop a multi-agency advisory service for artificial intelligence and data-driven technologies.
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
How my experience as a patient helped shape NICE guidelines for colorectal cancer
Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future.
A 'safe space' for addressing complex health technology assessment challenges
Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.